

# Hatem A Azim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9510449/publications.pdf>

Version: 2024-02-01

57  
papers

3,243  
citations

201385

27  
h-index

174990

52  
g-index

57  
all docs

57  
docs citations

57  
times ranked

4600  
citing authors

#	ARTICLE	IF	CITATIONS
1	Knowledge, Practice, and Attitudes of Physicians in Low- and Middle-Income Countries on Fertility and Pregnancy-Related Issues in Young Women With Breast Cancer. <i>JCO Global Oncology</i> , 2022, 8, e2100153.	0.8	6
2	Abstract P3-23-03: Use of taxane-containing regimens during pregnancy for the treatment of breast cancer: A systematic review. <i>Cancer Research</i> , 2022, 82, P3-23-03-P3-23-03.	0.4	1
3	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. <i>Cancer Research</i> , 2022, 82, PD5-06-PD5-06.	0.4	0
4	Clinical behavior and outcomes of breast cancer in young women with germline <i>BRCA</i> pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
5	Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case-control study. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 489-500.	1.1	10
6	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
7	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
8	Integrating PARP inhibitors into the management of breast cancer: where are we?. <i>Chinese Clinical Oncology</i> , 2021, 10, 50-50.	0.4	4
9	Clinical utility of genomic signatures in young breast cancer patients: a systematic review. <i>Npj Breast Cancer</i> , 2020, 6, 46.	2.3	29
10	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. <i>Journal of Clinical Oncology</i> , 2020, 38, 3012-3023.	0.8	69
11	Reply to S. A. Narod et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 4352-4354.	0.8	2
12	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
13	Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis. <i>Current Problems in Cancer</i> , 2020, 44, 100592.	1.0	1
14	Estimation of historical control rate for a single arm de-escalation study – Application to the POSITIVE trial. <i>Breast</i> , 2020, 53, 1-7.	0.9	13
15	Fertility preservation in patients with <i>BRCA</i> mutation. <i>Ecancelmedscience</i> , 2020, 14, 1033.	0.6	7
16	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young <i>BRCA</i> -mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	1.1	29
17	Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTO (BIG 1-06) and ALTO (BIG) Tj ETQq101 0.7843714 rgB	0.78	14
18	Response. <i>Journal of the National Cancer Institute</i> , 2018, 110, 919-920.	3.0	2

#	ARTICLE	IF	CITATIONS
19	Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. Journal of the National Cancer Institute, 2018, 110, 426-429.	3.0	143
20	Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology, 2018, 36, 981-990.	0.8	95
21	Response. Journal of the National Cancer Institute, 2018, 110, 541-541.	3.0	0
22	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	0.9	75
23	Estimation of historical control rate for a single arm de-escalation study: Application to the POSITIVE trial.. Journal of Clinical Oncology, 2018, 36, 552-552.	0.8	0
24	POSITIVE (IBCSG 48-14/BIG 8-13/A221405): Evaluating outcomes after interrupting endocrine therapy (ET) for women with endocrine responsive (ER+) early breast cancer (BC) who desire pregnancy.. Journal of Clinical Oncology, 2018, 36, TPS596-TPS596.	0.8	2
25	Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial. Journal of the National Cancer Institute, 2017, 109, .	3.0	13
26	Fertility and pregnancy issues in BRCA -mutated breast cancer patients. Cancer Treatment Reviews, 2017, 59, 61-70.	3.4	68
27	Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology, 2017, 35, 1421-1429.	0.8	116
28	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 23-32.	1.8	20
29	Response to "Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?"™. European Journal of Cancer, 2016, 54, 165-166.	1.3	2
30	Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. Journal of the National Cancer Institute, 2016, 108, djw037.	3.0	24
31	Reproductive behaviors and risk of developing breast cancer according to tumor subtype: A systematic review and meta-analysis of epidemiological studies. Cancer Treatment Reviews, 2016, 49, 65-76.	3.4	167
32	What is the role of informed decision-making?. Expert Review of Anticancer Therapy, 2016, 16, 893-893.	1.1	0
33	The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients. British Journal of Cancer, 2016, 115, 1471-1478.	2.9	45
34	Adjuvant chemotherapy in elderly patients with breast cancer: key challenges. Expert Review of Anticancer Therapy, 2016, 16, 661-671.	1.1	6
35	Cancer and fertility preservation: international recommendations from an expert meeting. BMC Medicine, 2016, 14, 1.	2.3	521
36	Potential Therapeutic Targets in Triple Negative Breast Cancer. Current Breast Cancer Reports, 2015, 7, 215-223.	0.5	1

#	ARTICLE	IF	CITATIONS
37	Final 10-year results of the Breast International Group 2008 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 1481-1489.	1.3	32
38	Pregnancy following breast cancer using assisted reproduction and its effect on long-term outcome. <i>European Journal of Cancer</i> , 2015, 51, 1490-1496.	1.3	64
39	Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy. <i>Breast</i> , 2015, 24, 290-293.	0.9	27
40	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	0.9	97
41	Targeted agents for cancer treatment during pregnancy. <i>Cancer Treatment Reviews</i> , 2015, 41, 301-309.	3.4	84
42	An update on PARP inhibitors moving to the adjuvant setting. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 27-41.	12.5	316
43	New Strategies in Breast Cancer: The Significance of Molecular Subtypes in Systemic Adjuvant Treatment for Small T1a,bN0M0 Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 6242-6246.	3.2	15
44	Locoregional treatment of breast cancer during pregnancy. <i>Gynecological Surgery</i> , 2014, 11, 279-284.	0.9	48
45	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
46	Neurofibromatosis type I with breast cancer: not only for women!. <i>Hereditary Cancer in Clinical Practice</i> , 2014, 12, 5.	0.6	12
47	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014, 21, 545-554.	1.6	58
48	Breast cancer arising at a young age: Do we need to define a cut-off?. <i>Breast</i> , 2013, 22, 1007-1008.	0.9	6
49	Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: A sub-study from the NeoALTO phase III trial. <i>Breast</i> , 2013, 22, 1060-1065.	0.9	33
50	Prognostic Impact of Pregnancy After Breast Cancer According to Estrogen Receptor Status: A Multicenter Retrospective Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 73-79.	0.8	215
51	Pattern of Rash, Diarrhea, and Hepatic Toxicities Secondary to Lapatinib and Their Association With Age and Response to Neoadjuvant Therapy: Analysis From the NeoALTO Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4504-4511.	0.8	60
52	Understanding the factors associated with the surgical management of early breast cancer. <i>Gland Surgery</i> , 2013, 2, 4-6.	0.5	8
53	Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). <i>Breast Cancer Research and Treatment</i> , 2012, 133, 387-391.	1.1	61
54	Safety of pregnancy following breast cancer diagnosis: A meta-analysis of 14 studies. <i>European Journal of Cancer</i> , 2011, 47, 74-83.	1.3	227

#	ARTICLE	IF	CITATIONS
55	Motherhood after breast cancer: searching for la dolce vita. Expert Review of Anticancer Therapy, 2011, 11, 287-298.	1.1	41
56	Managing cancer during pregnancy: what evidence do we have?. , 2011, 121, 29-34.		2
57	Simultaneous targeting of estrogen receptor and HER2 in breast cancer. Expert Review of Anticancer Therapy, 2010, 10, 1255-1263.	1.1	14